skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

70 Total results for product and free and sample content found

Pink Sheet

UK Votes To Leave The EU – Where Next For The Life Sciences?

UK Votes To Leave The EU – Where Next For The Life Sciences?

UK vote to leave the EU opens the prospect of years of negotiations over the union's future relationship with one of its most valued member states.

Topic Regulation Brexit BioPharmaceutical

Generics Bulletin

Time Is Short To Prepare For New Post-Brexit UK Regulation

Time Is Short To Prepare For New Post-Brexit UK Regulation

Guidance from the UK’s MHRA on post-Brexit arrangements relevant to the off-patent industry has been welcomed by local industry body the BGMA. However, it has warned that time is short to prepare for the end of the UK-EU transition period, with new guidance in certain areas “critical.”

Topic Brexit

Medtech Insight

Brexit Response: Patient Safety Prioritized In Forthcoming UK MHRA Device Regulatory System

Brexit Response: Patient Safety Prioritized In Forthcoming UK MHRA Device Regulatory System

Although the EU MDR and IVDR will fall outside the scope of new post-Brexit medtech regulations for Great Britain in 2021, the UK MHRA says it has the chance of developing its own world-leading regulatory regime.

Topic Medtech-Brexit Regulation Brexit

Pink Sheet

UK Explains Approach To Renewing Converted EU Drug Approvals in 2021

UK Explains Approach To Renewing Converted EU Drug Approvals in 2021

The Medicines and Healthcare products Regulatory Agency has put procedures in place to renew UK marketing authorizations that are grandfathered from the EU system after the Brexit transition period ends.

Topic EU Pharma-Brexit Brexit

Pink Sheet

Gloom Over Prospects For Brexit Trade Deal

Gloom Over Prospects For Brexit Trade Deal

With time running out on the UK-EU trade deal negotiations, the UK life sciences industry looks at the fine print of the new guidance on medicines regulation and explains why a mutual recognition agreement is urgently needed. 

Topic Pharma-Brexit Regulation Brexit

Pink Sheet

UK Offers Pragmatic Approach To Safety Reporting From Jan 2021

UK Offers Pragmatic Approach To Safety Reporting From Jan 2021

The UK’s approach to pharmacovigilance system requirements in the post-Brexit transition period will allow companies to leverage some of the existing structures put in place for EU systems.

Topic Pharma-Brexit Brexit

Pink Sheet

The Brexit Timebomb: Expect Effects On Drug Regulation, IP, Research And Trade

The Brexit Timebomb: Expect Effects On Drug Regulation, IP, Research And Trade

June 24 was a seismic day, in more ways than one. The UK's decision to withdraw from the EU may have elated more than half of the voting public, but it has caused deep disappointment, anxiety and anger among many millions more in the UK, Europe and around the world.

Topic Pharma-Brexit Brexit

Medtech Insight

UK Medtech Industry Advances Its Case For US FTA Amid Ongoing EU Talks

UK Medtech Industry Advances Its Case For US FTA Amid Ongoing EU Talks

Securing a favorable post-Brexit free trade agreement with the US is the principal aim of the UK’s Department for International Trade, and the UK medtech industry is pressing its case for closer business links with its largest non-EU trading partner.

Topic Medtech-Brexit Brexit Policy & Regulation

Medtech Insight

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

Topic EU Medtech-Brexit Regulation Brexit

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: